Boston Scientific has received U.S. FDA approval to expand the indication for current-generation INGEVITY+ Pacing Leads – thin wires placed inside the heart and connected to an implantable device – to include conduction system pacing and sensing of the left bundle branch area when connected to a single- or dual-chamber pacemaker.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific participates in a conference call with Piper Sandler
- Election 2024: Where To Put Your Money Ahead of the Vote
- Boston Scientific price target raised to $94 from $91 at Raymond James
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific obtains CE mark for ACURATE Prime Aortic Valve System